Go to the list of all blogs
Anna G's Avatar
published in Blogs
Feb 28, 2025

Exxon Mobil$109.87 ($XOM) Rises: Monthly Bullish Trend Predicted to Continue! πŸ›’οΈπŸ“ˆ"

Amid a global demand surge and economic rebound, Exxon Mobil Corp (NYSE: XOM) is shining brightly, steering towards a positive growth trajectory. A current stock price of $109.87, combined with advanced AI analysis, paints a promising future for the energy conglomerate.

If you're keen to explore trading opportunities in Exxon Mobil Corporation ($XOM), our AI robots have got you covered with strategies tailored to different market conditions:

πŸ“‰ "Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA)" offersΒ  of +60%. This AI robot is designed to help you navigate and make the most of markets on the decline.

πŸ“ˆ On the other hand, "Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA)" boasts of +46%, providing a strategy focused on capitalizing on markets that are on the rise.

With these AI tools, you can align your trading strategy with the current market direction and potentially enhance your trading outcomes when dealing with $XOM or similar stocks. Start making data-driven decisions today! πŸ“ŠπŸ’Ή

🎯 Predicted Growth:

A.I.dvisor forecasts an encouraging 4% growth for Exxon Mobil, anticipating a rise to $114.26 or even beyond in the upcoming month. Historical data analysis confirms an 86% probability for the bullish trend to continue, signaling a golden opportunity for traders.

πŸ“‰ Earnings Review:

The latest earnings report unveiled on July 28 hinted at an earnings per share (EPS) of $1.94, narrowly missing the estimated $2.04. Despite the slight setback, with a robust 30.12M shares in circulation, Exxon's market capitalization solidifies at a mammoth $421.93 billion.

πŸ’° Dividend Distribution:

Rewarding its shareholders, Exxon paid out a dividend of $0.91 per share recently. Investors should note the ex-dividend date of August 15, 2023; ensuring they purchase stocks prior to this date guarantees the receipt of this dividend, adding an extra incentive for potential investors.

πŸ” Industry Overview:

Integrated oil firms, including giants like Exxon Mobil, Chevron, and BP, span the entire oil value chain - from upstream activities like exploration to downstream endeavors like refining and marketing. Their financial performance often mirrors global crude oil price trends. For instance, if an entity has an extensive downstream sector, the negative impact of falling crude prices on its upstream activities might be counterbalanced by its downstream benefits.

🌍 Market Landscape:

Exxon, with its commanding market cap of $421.93B, dominates the Integrated Oil Industry. In this sector, market caps vary, ranging from a mere $39.76K to Exxon's towering valuation. Average valuations across the sector hover around $58.77B, illustrating Exxon's significant lead.

πŸ“Š Performance Metrics:

The past week showcased Exxon gaining +3.69%, with a daily trade volume averaging 2 million shares. Despite a -6.46% drawdown, the company has displayed resilience and adaptability. In a broader perspective, the Integrated Oil Industry has seen a weekly price growth of 5%, with a quarterly rise of 7%.

πŸ“ˆ Fundamental Ratings:

An array of fundamental analysis ratings are tabulated as follows:

  • Valuation Rating: 50
  • P/E Growth Rating: 56
  • Price Growth Rating: 48
  • SMR Rating: 44
  • Profit Risk Rating: 74
  • Seasonality Score: 30

Insights:

In a constantly evolving energy landscape, Exxon Mobil's recent performance and promising outlook make it a lucrative option for traders and investors. As the bullish trend is predicted to persist, it could be an opportune moment to consider Exxon in your portfolio strategy. Stay tuned and trade smart! πŸŒŸπŸŒπŸ›’οΈπŸ“Š

Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studioβ€”a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
When geopolitical turmoil sends markets into chaos, most retail traders freeze β€” but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 β€” trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire β€” literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent β€” a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated modelβ€”from discovery to commercializationβ€”drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.